Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1480MR)

This product GTTS-WQ1480MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1480MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7680MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ13774MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ4178MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ5516MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ15572MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ6030MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ10551MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ2809MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW